Zobrazeno 1 - 10
of 88
pro vyhledávání: '"M. Hagleitner"'
Autor:
Emma Kroeze, Michelle M. Kleisman, Lennart A. Kester, Marijn A. Scheijde‐Vermeulen, Edwin Sonneveld, Jessica G. C. Buijs‐Gladdines, Melanie M. Hagleitner, Friederike A. G. Meyer‐Wentrup, Margreet A. Veening, Auke Beishuizen, Jules P. P. Meijerink, Jan L. C. Loeffen, Roland P. Kuiper
Publikováno v:
HemaSphere, Vol 8, Iss 7, Pp n/a-n/a (2024)
Abstract Twenty percent of children with T‐cell lymphoblastic lymphoma (T‐LBL) will relapse and have an extremely poor outcome. Currently, we can identify a genetically low‐risk subgroup in pediatric T‐LBL, yet these high‐risk patients who
Externí odkaz:
https://doaj.org/article/f691a15ba3c94664ba8c567a4dea1811
Autor:
Evelien G. E. Hurkmans, Jan B. Koenderink, Jeroen J. M. W. van den Heuvel, Yvonne M. H. Versleijen-Jonkers, Melissa H. S. Hillebrandt-Roeffen, Johanne M. Groothuismink, Hanneke I. Vos, Winette T. A. van der Graaf, Uta Flucke, Grigor Muradjan, Hendrik W. B. Schreuder, Melanie M. Hagleitner, Han G. Brunner, Hans Gelderblom, Anne-Marie Cleton-Jansen, Henk-Jan Guchelaar, Eveline S. J. M. de Bont, Daan J. Touw, G. Jan Nijhoff, Leontien C. M. Kremer, Huib Caron, Rachael Windsor, Ana Patiño-García, Anna González-Neira, Federica Saletta, Geoff McCowage, Sumanth Nagabushan, Daniel Catchpoole, D. Maroeska W. M. te Loo, Marieke J. H. Coenen
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Despite (neo) adjuvant chemotherapy with cisplatin, doxorubicin and methotrexate, some patients with primary osteosarcoma progress during first-line systemic treatment and have a poor prognosis. In this study, we investigated whether pati
Externí odkaz:
https://doaj.org/article/41ddb83527fc4a9bae06e65f39652d1c
Autor:
Emma Kroeze, Dilys D. Weijers, Melanie M. Hagleitner, Hester A. de Groot-Kruseman, Marjolijn C. J. Jongmans, Roland P. Kuiper, Rob Pieters, Jules P. P. Meijerink, Jan L. C. Loeffen
Publikováno v:
HemaSphere, Vol 6, Iss 1, p e668 (2022)
This study describes the clinical characteristics of a complete Dutch T-cell lymphoblastic lymphoma (T-LBL) cohort, including second primary malignancies and comorbidities. We show that over 10% of patients in this complete T-LBL cohort have been dia
Externí odkaz:
https://doaj.org/article/edb66bd8c25f4a0b9bc5d4598177b458
Autor:
Emma Kroeze, Laura Arias Padilla, Max Bakker, Judith M. Boer, Melanie M. Hagleitner, Birgit Burkhardt, Takeshi Mori, Andishe Attarbaschi, Jaime Verdú-Amorós, Marta Pillon, Liliya Anderzhanova, Edita Kabíčková, Alan K. S. Chiang, Rejin Kebudi, Karin Mellgren, Jelena Lazic, Janez Jazbec, Jules P. P. Meijerink, Auke Beishuizen, Jan L. C. Loeffen
Publikováno v:
Cancers, Vol 14, Iss 16, p 3895 (2022)
B-cell lymphoblastic lymphoma (BCP-LBL) and B-cell acute lymphoblastic leukemia (BCP-ALL) are the malignant counterparts of immature B-cells. BCP-ALL is the most common hematological malignancy in childhood, while BCP-LBL accounts for only 1% of all
Externí odkaz:
https://doaj.org/article/c455fae28e1d4263899563bbfb0705fe
Autor:
Evelien G. E. Hurkmans, Marije J. Klumpers, Sita H. Vermeulen, Melanie M. Hagleitner, Uta Flucke, H. W. Bart Schreuder, Hans Gelderblom, Johannes Bras, Henk-Jan Guchelaar, Marieke J. H. Coenen, D. Maroeska W. M. te Loo
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
High-dose methotrexate is a cornerstone agent in the chemotherapeutic treatment of patients with osteosarcoma. However, patients often develop methotrexate-induced toxicities. We aim to identify determinants of methotrexate-induced toxicities in oste
Externí odkaz:
https://doaj.org/article/c702ae5dc3b84a2bb86d47681b47a68d
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
In the past decades, new cancer treatments have been introduced in pediatric oncology leading to improvement in clinical outcomes and survival rates. However, due to inter-individual differences, some children experience severe chemotherapy-induced t
Externí odkaz:
https://doaj.org/article/56a9b853eee64bb7a0f3795bac3a6fc2
Autor:
Dunja M.W.M te Loo, Henk-Jan Guchelaar, Peter M. Hoogerbrugge, Frank N. van Leeuwen, Uta Flucke, H.W. Bart Schreuder, Winette T.A. van der Graaf, Eveline S.J.M. de Bont, Hanneke I. Vos, Remco R. Makkinje, Hans Gelderblom, Marieke J.H. Coenen, Melanie M. Hagleitner
Supplementary Table 3. Genetic variants associated with 5-year PFS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::373af66ca7e1657a72c7d47c2e65c4f8
https://doi.org/10.1158/1078-0432.22454916
https://doi.org/10.1158/1078-0432.22454916
Autor:
Dunja M.W.M te Loo, Henk-Jan Guchelaar, Peter M. Hoogerbrugge, Frank N. van Leeuwen, Uta Flucke, H.W. Bart Schreuder, Winette T.A. van der Graaf, Eveline S.J.M. de Bont, Hanneke I. Vos, Remco R. Makkinje, Hans Gelderblom, Marieke J.H. Coenen, Melanie M. Hagleitner
Supplementary Table 2. Genetic variants associated with histologic response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7425f23f113b4c402bb1214257e49f1f
https://doi.org/10.1158/1078-0432.22454919
https://doi.org/10.1158/1078-0432.22454919
Autor:
Dunja M.W.M te Loo, Henk-Jan Guchelaar, Peter M. Hoogerbrugge, Frank N. van Leeuwen, Uta Flucke, H.W. Bart Schreuder, Winette T.A. van der Graaf, Eveline S.J.M. de Bont, Hanneke I. Vos, Remco R. Makkinje, Hans Gelderblom, Marieke J.H. Coenen, Melanie M. Hagleitner
Purpose: Overall survival in patients with osteosarcoma is only 60%. Poor response to chemotherapy is the dominant risk factor for poor survival. Pharmacogenetic research can offer possibilities to optimize treatment and improve outcome. We applied a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20536c0c0ae4a3cf902db4fbfba75548
https://doi.org/10.1158/1078-0432.c.6522873
https://doi.org/10.1158/1078-0432.c.6522873
Autor:
Dunja M.W.M te Loo, Henk-Jan Guchelaar, Peter M. Hoogerbrugge, Frank N. van Leeuwen, Uta Flucke, H.W. Bart Schreuder, Winette T.A. van der Graaf, Eveline S.J.M. de Bont, Hanneke I. Vos, Remco R. Makkinje, Hans Gelderblom, Marieke J.H. Coenen, Melanie M. Hagleitner
Supplementary Table 1. Set of 381 SNPs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70abd06bb2871ef7ba9f30af68e6fad6
https://doi.org/10.1158/1078-0432.22454922.v1
https://doi.org/10.1158/1078-0432.22454922.v1